4th Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

FDA Appropriations FY10. H.R. 3590, Patient Protection and Affordable Care Act, Title III, all provisions relating to "medication therapy management," "medical home," and "independence at home." H.R. 3962, Affordable Health Care for America Act, Title II, all provisions relating to Frontline Health Providers and Loan Forgiveness; Title III all provisions relating to "medical home" and "independence at home;" Title V, all provisions relating to "medication therapy management." Communcations to House and Senate supporting residency funding. Communication with FDA on market withdrawal of unapproved nitroglycerin.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Employment & Training Administration; Centers For Disease Control & Prevention (CDC); Drug Enforcement Administration (DEA)

Bills named: H.R. 3590 (111th), H.R. 3962 (111th)

Labor Issues/Antitrust/Workplace LBR

Communication to Employment and Training Administration relating to awarding competitive grants for worker training to ASHP-accredited pharmacy technician training programs. Communication to National Institute for Occupational Safety and Health relating to temporary assignment for health care workers who work with hazardous drugs.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Centers For Disease Control & Prevention (CDC); Employment & Training Administration; HOUSE OF REPRESENTATIVES; SENATE; Drug Enforcement Administration (DEA); Food & Drug Administration (FDA)

Pharmacy PHA

S. 252, Veterans Health Care Authorization of 2009, Title I, all provisions relating to incentive pay for pharmacists. Communications with FDA regarding Risk Evaluation and Mitigation Strategies, Medication Guides, and providing effective information to consumers about prescription drug risks and benefits. Communication with DEA regarding the identification of institution-based individual practitioners.

LobbyistCovered position, as disclosed
JUSTINE COFFEY —
JOSEPH M HILL —
BRIAN M MEYER —
GERALYN TRUJILLO —

Contacted: Centers For Disease Control & Prevention (CDC); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; SENATE; Employment & Training Administration; Food & Drug Administration (FDA)

Bills named: S. 252 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.